| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgement to Referees
|
|
|
|
|
6 |
p. 323-325
|
artikel
|
| 2 |
Acknowledgement to Referees
|
|
|
|
|
6 |
p. 319-321
|
artikel
|
| 3 |
Acknowledgement to Referees
|
|
|
|
|
6 |
p. 363-364
|
artikel
|
| 4 |
Acknowledgement to referees
|
|
|
|
|
6 |
p. 441-444
|
artikel
|
| 5 |
American Geriatrics Society Annual Scientific Meeting (AGS 2023)
|
Herdson, Caroline
|
|
|
|
6 |
p. 491-493
|
artikel
|
| 6 |
Correction to: The Impact of the Priority Review Voucher on Research and Development for Tropical Diseases
|
Aerts, Celine
|
|
|
|
6 |
p. 405
|
artikel
|
| 7 |
Current Challenges in Labelling for Generic Medicinal Products: Company Core Data Sheet (CCDS) Development and Maintenance
|
Mueller, Marion
|
|
|
|
6 |
p. 381-386
|
artikel
|
| 8 |
Drug Repurposing for Spinal Cord Injury: Progress Towards Therapeutic Intervention for Primary Factors and Secondary Complications
|
Guha, Lahanya
|
|
|
|
6 |
p. 463-490
|
artikel
|
| 9 |
Effectiveness of Additional Risk Minimization Measures for Atezolizumab in the European Union
|
Patel, Hina
|
|
|
|
6 |
p. 339-351
|
artikel
|
| 10 |
Forum
|
|
|
|
|
6 |
p. 377-386
|
artikel
|
| 11 |
Forum
|
|
|
|
|
6 |
p. 407-413
|
artikel
|
| 12 |
Forum
|
|
|
|
|
6 |
p. 333-341
|
artikel
|
| 13 |
Forum
|
|
|
|
|
6 |
p. 349-363
|
artikel
|
| 14 |
Forum
|
|
|
|
|
6 |
p. 371-377
|
artikel
|
| 15 |
Journal Watch
|
|
|
|
|
6 |
p. 387-396
|
artikel
|
| 16 |
Journey from an Enabler to a Strategic Leader: Integration of the Medical Affairs Function in ESG Initiatives and Values
|
Furtner, Daniel
|
|
|
|
6 |
p. 405-416
|
artikel
|
| 17 |
Key Characteristics of Database Studies on Drug Effectiveness in the Postmarketing Stage: A Systematic Review
|
Shiragasawa, Chihaya
|
|
|
|
6 |
p. 327-338
|
artikel
|
| 18 |
Major Pharmaceutical Conferences and Courses: February to March 2023
|
|
|
|
|
6 |
p. 401-403
|
artikel
|
| 19 |
Major Pharmaceutical Conferences and Courses: February to March 2022
|
|
|
|
|
6 |
p. 371-374
|
artikel
|
| 20 |
Major Pharmaceutical Conferences and Courses: February to March 2021
|
|
|
|
|
6 |
p. 415-416
|
artikel
|
| 21 |
Major Pharmaceutical Conferences and Courses: February 2024 to March 2024
|
|
|
|
|
6 |
p. 495-497
|
artikel
|
| 22 |
Plain Language Summaries of Clinical Trial Results: A Preliminary Study to Assess Availability of Easy-to-Understand Summaries and Approaches to Improving Public Engagement
|
Penlington, Michael
|
|
|
|
6 |
p. 401-406
|
artikel
|
| 23 |
Potential Role of Polyphenolic Flavonoids as Senotherapeutic Agents in Degenerative Diseases and Geroprotection
|
Mbara, Kingsley C.
|
|
|
|
6 |
p. 331-352
|
artikel
|
| 24 |
Practical Considerations for the Implementation and Monitoring of Risk Minimisation Measures for High-Risk Teratogenic Medicines
|
Mueller, Marion
|
|
|
|
6 |
p. 439-449
|
artikel
|
| 25 |
Risk Minimisation Evaluation with Process Indicators and Behavioural or Health Outcomes in Europe: Systematic Review
|
Artime, Esther
|
|
|
|
6 |
p. 387-400
|
artikel
|
| 26 |
Strengthening the Cost Effectiveness of Medical Countermeasure Development Against Rare Biological Threats: The Ebola Outbreak
|
Johnson, Mark Lawrence
|
|
|
|
6 |
p. 423-436
|
artikel
|
| 27 |
Strengthening the Pharmacovigilance System in Mexico: Implementation of VigiFlow and VigiLyze, as ICSR and Signal Detection Management Systems
|
Rayón-Ramírez, Gandi
|
|
|
|
6 |
p. 425-437
|
artikel
|
| 28 |
37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021): 13–15 October, 2021
|
Pochon, Sue
|
|
|
|
6 |
p. 367-370
|
artikel
|
| 29 |
The Characteristics of Clinical Trials on Cannabis and Cannabinoids: A Review of Trials for Therapeutic or Drug Development Purposes
|
Modaresi, Farhang
|
|
|
|
6 |
p. 387-400
|
artikel
|
| 30 |
The Effectiveness and Safety of Cannabidiol in Non-seizure-related Indications: A Systematic Review of Published Randomized Clinical Trials
|
Tang, Yuni
|
|
|
|
6 |
p. 353-385
|
artikel
|
| 31 |
The Emergence of Regulatory Science in Pharmaceutical Medicine
|
Callréus, Torbjörn
|
|
|
|
6 |
p. 345-351
|
artikel
|
| 32 |
The Pharmaceutical Year That Was, 2022
|
Fox, Anthony W.
|
|
|
|
6 |
p. 327-330
|
artikel
|
| 33 |
The Pharmaceutical Year that was, 2021
|
Fox, Anthony W.
|
|
|
|
6 |
p. 323-325
|
artikel
|
| 34 |
The Pharmaceutical Year That Was, 2020
|
Fox, Anthony W.
|
|
|
|
6 |
p. 365-368
|
artikel
|
| 35 |
The Pharmaceutical Year That Was, 2023
|
Fox, Anthony W.
|
|
|
|
6 |
p. 401-404
|
artikel
|
| 36 |
The Pharmacokinetics of Drugs Delivered to the Upper Nasal Space
|
Shrewsbury, Stephen B.
|
|
|
|
6 |
p. 451-461
|
artikel
|
| 37 |
The Unintended Consequences of Adverse Event Information on Medicines’ Risks and Label Content
|
Furlan, Giovanni
|
|
|
|
6 |
p. 369-380
|
artikel
|
| 38 |
The Value and Deliverables of Medical Affairs: Affiliate Perspectives and Future Expectations
|
Farrington, Anupma Dhanda
|
|
|
|
6 |
p. 417-424
|
artikel
|
| 39 |
To Tweet or Not to Tweet: A Longitudinal Analysis of Social Media Use by Global Diabetes Researchers
|
Leigh, Simon
|
|
|
|
6 |
p. 353-365
|
artikel
|
Tijdschrift beschrijving